Sequential vs. concurrent systemic therapies in combination with FOLFOX-HAIC for locally advanced hepatocellular carcinoma: a single-center, real-world cohort study
Our study revealed that sequential systemic ICIs and TKIs in combination with FOLFOX-HAIC provides similar long-term prognosis and better tolerability compared to concurrent therapy for locally advanced HCC patients. Prospective studies with a larger sample size and longer follow-up are required to validate these findings.
Authors
- Dandan Hu (ORCID: https://orcid.org/0000-0001-7905-8536)
- Yangxun Pan (ORCID: https://orcid.org/0000-0002-3887-5852)
- Huilan Zeng (ORCID: https://orcid.org/0000-0003-1701-3660)
- Yaojun Zhang (ORCID: https://orcid.org/0000-0002-9752-4729)
- Wa Xie
- Minshan Chen (ORCID: https://orcid.org/0000-0002-6741-7498)
- Zhenyun Yang
- Zhiwen Hu (ORCID: https://orcid.org/0000-0002-3472-6083)
- Li‐Yang Sun (ORCID: https://orcid.org/0009-0007-8143-0836)
- Zhongguo Zhou
Institutions
- Sun Yat-sen University (CN)
- Sun Yat-sen University Cancer Center (CN)
Publication Details
- Journal
- BMC Cancer
- Published
- 2024-09-19
- DOI
- https://doi.org/10.1186/s12885-024-12940-0
- Citations
- 7
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 2.59
Funders
- National Natural Science Foundation of China